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Abstract
Introduction: Parallel to the advances in diagnostic imaging using positron emission tomography
(PET), and availability of new systemic treatment options, the treatment paradigm in oncology has
shifted towards more aggressive therapeutic interventions to include cytoreductive techniques and
metastasectomies. Intraoperative localization of PET positive recurrent/metastatic lesions can be
facilitated using a hand-held PET probe.
Materials and methods: Records of patients who underwent PET probe-guided surgery were
reviewed. Surgical indications and operative targets were determined based on diagnostic PET/
PET-CT images performed prior to probe-guided surgical planning. PET probe-guided surgery was
performed on a separate day using a high-energy gamma probe (PET probe, Care Wise Medical,
Morgan Hills CA) 2–6 hours post-injection of 5–15 mCi FDG. Probe count rates, target-to-
background ratios, and lesion detection success were analyzed.
Results: Twenty-four patients underwent PET probe-guided surgery; one patient had two PET-
probe guided surgeries resulting in a total of 25 cases (5 colorectal cancer cases, 4 thyroid cancer
cases, 6 lymphoma cancer cases, and 10 other cancer cases). Surgical indication was diagnostic
exploration in 6 cases with lymphoma and 1 case with head and neck cancer (28%). The remaining
18 cases (72%) underwent PET probe-guided surgery with a therapeutic intent in a recurrent or
metastatic disease setting. All the lesions identified and targeted on a preoperative FDG-PET scan
were detected by the PET probe with satisfactory in-vivo lesion count rates and a TBR of ≥ 1.5.
PET probe allowed localization of lesions that were non-palpable and non-obvious at surgical
exploration in 8 patients.
Conclusion: The use of the PET probe improves the success of surgical exploration in selected
indications. Separate day protocol is clinically feasible allowing for flexible operating room
scheduling.
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Background
Gamma probes have been used in medicine and surgery
since the mid 1940s. There have been significant technical
improvements in probe technology, including a number
of clinical applications that have now become standard
procedures in contemporary oncologic surgery [1-9]. The
introduction of FDG-PET in functional imaging in recent
years has markedly improved cancer detection and man-
agement. The oncological applications of PET are rapidly
expanding with development of new positron-emitting
radiopharmaceuticals. Parallel to the advances in PET
imaging, and availability of new systemic treatment
options, the treatment paradigm in oncology has also
shifted towards more aggressive therapeutic interventions
including cytoreductive techniques and metastasecto-
mies. This new strategy applies to a number of malignan-
cies including, but not limited to thyroid cancer,
neuroendocrine tumors, colorectal cancer (CRC), and
melanoma [11-15].
Intraoperative localization of PET-positive recurrent/met-
astatic lesions can be facilitated using a hand-held PET
probe. PET probe essentially is a high energy gamma
probe that is designed to process the 511 keV photons of
PET tracers. Intraoperative gamma probe performance, as
a general rule, is a function of radiopharmaceutical
uptake, clearance kinetics, and probe engineering, all ulti-
mately determining the target to background ratio (TBR)
and detection threshold. A minimum TBR of 1.5:1 is
needed in the operative field for the operating surgeon to
be comfortable that the differences between tumor tissue
and normal adjacent tissue are real [10]. Due to the high
energy photon fluxes, achieving a satisfactory TBR intra-
operatively is highly challenging. As such, the clinical use
of PET probes has been limited to clinical trial settings,
and no standard PET probe-guided surgery protocol has
been developed.
PET probe is used routinely in the surgical oncology prac-
tice at the Center for Cancer Care at Goshen Health Sys-
tem. This paper discusses the indications and the clinical
utility of the PET probe technique, and a PET probe-
guided surgery protocol.
Materials and methods
Study design and conduct
This study is a retrospective review of 25 cases collected
over a period of 18 months. Clinical and operative
reports, imaging data and pathology reports were
reviewed. Chart review was conducted with the approval
of Institutional Review Board and with adherence to
HIPAA rules. The objectives of this study were to validate
(establish) a clinical protocol for PET probe-guided sur-
gery, and to assess the clinical utility of the technique.
PET probe-guided surgery protocol
All patients underwent an FDG-PET study either using a
stand-alone PET system or a PET-CT scanner under stand-
ard clinical protocol. Images were obtained 60–90 min-
utes after FDG administration. Images were reviewed by a
nuclear physician and a surgical oncologist. Standard
uptake values (SUV) of the target lesion(s) were meas-
ured. The PET probe-guided surgery decision was made
after careful review of the imaging information and the
clinical indications at a multidisciplinary conference.
The patients received an intravenous injection of 5–15
mCi FDG the morning of planned surgery. Physical activ-
ity was kept to a minimum with a quiet time of 60 min-
utes post-injection. Patients were routinely hydrated with
100–150 ml/hr NS infusion. Surgical exploration was
scheduled between 2–6 hours post injection of the radi-
opharmaceutical. Higher FDG activity was chosen if the
surgery was scheduled more than six hours post injection.
No glucose containing IV fluids were allowed prior to and
during the operation. Relevant images/views were made
available for viewing in the operating room.
A high-energy gamma probe with a GSO crystal and 12.5
mm tungsten shielding (Care Wise Medical, Morgan Hills,
CA) were used. The Analyzer was set for a photopeak of
511 keV, Window of 20%, and a threshold of 490 keV.
Calibration of the system and appropriate settings were
verified prior to each operation. The probe with its con-
necting cord was placed in a plastic sleeve. Surgical explo-
ration commenced with determining the probe survey
field. Initial probe survey is performed using the count per
second mode. A TBR of 1.5 and above was used for confir-
mation of the target localization.
Results
Patient, disease and lesion characteristics
Records of 24 patients (10 women, 14 men) ages 21–82
years were reviewed. All patients had a whole body FDG-
PET scan and a diagnostic CT imaging. A conformational
surgical pathology report was available for each case.
Working diagnoses were CRC in 4 patients (5 cases), thy-
roid cancer in 4, lymphoma in 6, breast cancer in 1,
melanoma in 1, adrenocortical cancer in 1, gastrointesti-
nal stromal tumor in 1, gastric cancer in 2, ovarian cancer
in 1, head and neck cancer in 2, and lung cancer in 1
patient. PET probe-guided exploration was conducted in
the neck in 7 (thyroid cancer: 4, lymphoma: 1, head and
neck cancer: 2), axilla in 3 (breast cancer: 1, lymphoma:
2), groin in 3 (lymphoma: 2, melanoma: 1), abdomen in
9 (colorectal cancer: 5, GIST: 1, gastric cancer: 2, ovarian
cancer: 1), neck and mediastinum in 1 (thyroid cancer),
mediastinum and abdomen in 1 (adrenocortical cancer),
and in chest in 1 (lung cancer). Patient and disease char-
acteristics are listed in Table 1.W
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Table 1: Disease, surgical procedure, and clinical outcome report TBR values indicate intraoperative probe measurements
Case # Diagnosis Operation Probe Utility Time (hrs) SUV TBR Count/Sec
1 Lymphoma Excisional Biopsy, Groin Localized the non-palpable target (A) 6 7.1 2.0 302
2 Recurrent non-Iodine avid Thyroid Cancer Anterior Neck Dissection Localized non-palpable metastatic lymph nodes (A) 6 6.4 1.5 166
3 Recurrent non-Iodine avid Thyroid Cancer Central Neck Dissection Localized the non-palpable target (A) 6 7.0 1.6 546
4 Adrenocortical Cancer Sternotomy/Laparatomy Lung/Liver Resection Localized difficult to access metastatic lymph nodes (A) 6 4.0 1.8 450
5 Ovarian Cancer Exploratory Laparatomy Metastasectomy Confirmatory (B) 4 39.8 1.5 297
6 Gastric Cancer Gastrectomy Extended Node dissection Localized surgically occult node (A) 4 6.1 1.8 150
7 Colon Cancer Exploratory Laparatomy Periaortic Dissection Localized difficult to access metastatic lymph nodes (A) 2 9.1 1.5 1067
8 Lung Thoracotomy Confirmatory (B) 4 4.0 1.5 1152
9 Lymphoma Axilla Lymph Node Excision Confirmatory (B) 6 4.4 1.8 125
10 Groin Lymphoma Excision Confirmatory (B) 4 4.9 2.2 172
11 GIST-Pertonial Implant Exploratory cytoreduction Confirmatory (B) 6 9.5 1.9 165
12 Recurrent non-iodine avid Thyroid Cancer Central Neck Dissection Localized non-palpable metastatic lymph nodes (A) 6 19.6 2.4 540
13 Lymphoma Excisional Biopsy, Neck Localized the non-palpable target (A) 6 7.7 3.8 173
14 Lymphoma Excisional Biopsy, Groin Localized the non-palpable target (A) 6 3.6 1.5 749
15 Gastrointestinal Stromal Tumor Exploratory Laparatomy Liver Resection Confirmatory (B) 6 4.3 1.5 690
16 Recurrent non-iodine avid Thyroid Cancer Neck and Mediastinal Node dissection Localized difficult to access metastatic lymph nodes (A) 6 7.7 1.7 361
17 Lymphoma Excisional Biopsy, Axilla Localized the non-palpable target (A) 6 3.3 1.8 828
18 Breast Cancer Axillary Dissection Confirmatory (B) 4 3.6 1.8 754
19 Colon Cancer Liver Resection Exploratory Laparatomy Confirmatory (B) 6 12.5 1.8 148
20 Branchial cancer Excision Localized the non-palpable target (A) 6 9.6 1.5 602
21 Colon Cancer Laparatomy Celiac Node Dissection Localized difficult to access metastatic lymph nodes (A) 4 6.1 2.0 127
22 Unknown Primary – Thigh Soft Tissue Excisional Biopsy Negative surgical exploration (C) 6 15.8 N/A N/A
23 Colon Cancer Liver Resection Exploratory Laparatomy Confirmatory (B) 6 5.2 3.8 150
24 Colon Cancer Exploratory Laparatomy Periaortic Dissection Localized difficult to access metastatic lesions (A) 6 4.5 2.1 894
25 Head and Neck Cancer Escisional biopsy Localized the non-palpable target (A) 4 8 2 210
Outcome Legend:
(A): Category-A where the probe's use was instrumental and resulted in direct surgical benefit. (B): Category-B where the probe's use was confirmatory with no direct impact on surgical performance. (C): 
Category-C where the probe did not locate the image-positive lesion.World Journal of Surgical Oncology 2007, 5:65 http://www.wjso.com/content/5/1/65
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Quantitative measurements and probe performance
PET probe-guided surgical exploration indications were
based on the presence of at least one target lesion. All tar-
get lesions had an SUV > 3 (Range: 3.2–39.8). PET probe
detected all FDG-PET image positive lesions. None of the
lesions were immediately apparent at the surgical explora-
tion. The smallest detectable lesion was 0.8 cm. The probe
did not identify any lesion(s) that were not seen in preop-
erative imaging. Surgery was performed at 2 h post-injec-
tion in 1 case, at 4 h post-injection in 7, and at 6 h post-
injection in 17 cases. No compromise in probe sensitivity
was noted up to 6 h post-injection with 15 mCi adminis-
tered activity. A trend towards an increase in TBR was
observed with increasing time interval between the injec-
tion and surgical exploration, however, this difference was
not statistically significant.
In patients with lymphoma the PET probe was used to
locate a non-palpable lymph node during a diagnostic
lymphadenectomy. The PET probe successfully located
the target lymph nodes (neck, axilla and groin) in all
cases. Figures 1, 2, 3 show a case of head and neck cancer
where PET probe was used for diagnostic lymphadenec-
tomy in the neck. In patients who underwent a metasta-
sectomy procedure, surgical exploration was clearly
facilitated by the use of the probe. It helped lead to the
successful accomplishment of the surgical end-point
(resection of the image-detected lesion). Probe-guided
exploration was most rewarding in secondary explora-
tions where the lesion(s) were obscured by the scar tissue.
Manipulation of the probe in the surgical field was easy
without any access difficulties. PET probe-guided surgery
protocol is detailed in Table 2.
Discussion
The success of a PET probe-guided surgery depends on
numerous factors including the FDG avidity of the tumor,
timing of surgical exploration in reference to injection of
FDG, anatomic location of the lesion, its relative proxim-
ity to main sites of physiologic uptake/accumulation, and
technical properties of the probe. The current study was
performed to review the performance of the PET probe in
surgical practice, and to validate/establish the optimal
surgical protocol. Surgical performance was evaluated
based on the probe's the ability to identify lesions seen on
diagnostic imaging, and more importantly, actual contri-
bution to the surgical exploration.
PET-probe guided excision of FDG-positive lymph node in  the neck Figure 3
PET-probe guided excision of FDG-positive lymph node in 
the neck. Final pathology confirmed metastatic squamous cell 
cancer.
FDG-PET/CT scan of a patient with nasopharyngeal cancer Figure 1
FDG-PET/CT scan of a patient with nasopharyngeal cancer. 
Transverse slice demonstrating FDG-positive primary site
Transverse slice demonstrating FDG-positive lymph node Figure 2
Transverse slice demonstrating FDG-positive lymph node. 
An US-guided FNA of this node was non-diagnostic.World Journal of Surgical Oncology 2007, 5:65 http://www.wjso.com/content/5/1/65
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All the lesions identified on imaging studies were detected
by the PET probe. The size of the lesions varied from 0.8
cm to 4 cm. The PET probe, however, was clearly most
useful in detection of surgically occult lesions. Occult
lesion was defined as a lesion that was not easily seen or
palpated during routine surgical exploration. Some occult
lesions included tumor masses measuring 2 cm or above.
These were located in regions where the immediate surgi-
cal access was difficult due to a barrier of adhesions or scar
tissue. A posterior mediastinal exploration and two
abdominal re-explorations for recurrent nodal disease
involving periportal and celiac regions that were compli-
cated with severe scarring were successfully completed
using the PET probe. PET probe effectively directed the
surgeon to the lesion(s) which were not found on initial
visual and manual exploration. In a patient with meta-
static gastric cancer, a N2 node was located using the
probe and included in the resection which otherwise
could have been retained following the planned gastrec-
tomy. Locating a lesion that is expected to be masked
under a scar tissue is probably the strongest indication for
PET probe-guided exploration. In a diagnostic setting, we
have found PET probe to be very useful in patients with
lymphoma who require restaging or regrading of their dis-
ease in follow-up. The patients most suitable for this
approach are those presenting with non-palpable but
FDG-PET positive lymph nodes in axilla, where a surgical
dissection is relatively more challenging than that of the
groin or neck.
The design of a probe that has the ability to process 511
keV photons, and its intraoperative use against significant
background activity is technically challenging. We have
previously demonstrated the efficacy and feasibility of
PET probe-guided surgical exploration in different clinical
settings in a phase II diagnostic study [10]. The technical
performance of a probe system is determined by detector
sensitivity, spectral resolution, scatter rejection electron-
ics, and shielding [11]. Optimum lesion detectability
requires high counting efficiency, an adequate shielding
method, and electronics capable of discriminating target
signal from radiation noise. Our review of data revealed
that there was a trend of TBR improving over time.
Improved TBRs (although they were not statistically sig-
nificant) were observed six hours after FDG administra-
tion. There was satisfactory count rate and TBR for surgical
detection up to 6 hours post-administration of 15 mCi
activity, which makes this technique clinically feasible.
Detector material for the probe plays an important role in
the sensitivity of the system. A GSO crystal is known to
have a better stopping power than the NaI or CsI crystals
and much better efficiency than the semiconductors used
in medium energy gamma probes [16]. The PET probe
also has to have heavier shielding. The profile, size and
the weight of the probe and the ergonomics of the probe
have to be non-restrictive to surgical exploration. The ana-
lyzer of the probe system allows exclusion of scattered
radiation which determines the specificity of the system.
Therefore, analyzer electronics are equally (if not more)
important in the overall performance of the probe system.
Poor electronic suppression of scattered photons seriously
degrades the TBR. This can cause small target lesions to be
missed in the background. Effective electronic suppres-
sion of scattered photons requires a precisely placed pho-
ton energy acceptance window set atop a scatter rejecting
threshold.
FDG avidity is determined by glycolytic activity of the
tumor and the viable tumor concentration in a given
Table 2: PET probe-guided surgery protocol for F-18 FDG
FDG-positive Tumor/Lesion Localization Protocol
Radiopharmaceutical • F-18-FDG
Activity/Administration • 5–15 mCi/IV injection (Use higher doses if the operation is scheduled more than 4 h post-injection)
Standard Imaging Protocol • Performed using standard clinical protocol
Timing of Surgical Exploration • 2–6 h post-injection
Patient Preparation • NPO × 6 hours
• Blood glucose control in diabetics (Blood glucose ≤ 140 at the time of FDG injection)
• 1 hour quiet time
• Hydration with Normal Saline @ 100–150 cc/h (No glucose containing fluids)
• Consider β-blockers ± Diazepam for head and neck cases
Gamma Probe • PET probe (High-energy gamma probe with photopeak detection capability over at 511 keV)
System set-up • Analyzer Settings: Photopeak: 511 keV, Window: 20%, Threshold: 490 keV (In commercial systems this is 
obtained by switching the isotope selection to PET (FDG) setting)
• Verify calibration and settings of the system
• Cover the probe with sterile plastic sleeve
Intra-operative Use • Point probe tip away from physiologic sites of uptake/accumulation (Foley catheter avoids bladder background)
• Probe survey at counts- per-second mode (Dynamic pitch range feed-back helpful)
• Hot-spot confirmation with TBR > 1.5 at 10-second count mode (TBR ratio feed-back helpful)
• Avoid simultaneous electrocautery useWorld Journal of Surgical Oncology 2007, 5:65 http://www.wjso.com/content/5/1/65
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lesion. This feature contributes to the success of probe
detection; however, it has nothing to do with the specifi-
city. Individual cancer types may also show significant
variability in terms of FDG avidity. Even in the same
patient, different lesions may have different degrees of
FDG uptake. The probe detects any FDG avid lesion
whether it is malignant or inflammatory.
FDG metabolism and clearance occurs at a much faster
rate in normal tissues than tumor tissue, and thus TBR
improves with time resulting in better lesion detection
when imaging is delayed [17]. We have observed that
tumor-to-non-tumor and tumor-to-organ rations were
higher for the delayed images than for the 1.5-h routine
images, and lesion detectability was improved in nodal
and hepatic metastases. Our current study indicated that
longer intervals accentuated the TBR, and resulted better
lesion detection. The background radiation tends to
decrease while the tumor uptake is retained. The in-situ
TBR is also strongly affected by the areas of physiologic
uptake or accumulation. The brain uptake in the head and
neck region, cardiac uptake in the chest, kidney uptake
and the accumulation inside the bladder in the abdomen
and pelvis affect the in-situ TBR. Areas of physiologic
uptake show attenuation over time, and use of an intraop-
erative bladder catheterization minimizes interference
from bladder accumulation of FDG.
The role of surgery in recurrent/metastatic cancer is being
redefined. With the advance of tools or early diagnosis,
and the improvements in systemic therapy, metastasec-
tomy and cytoreductive surgical techniques in selected
cases are considered viable management options. The
clinical indications for metastasectomy and/or cytoreduc-
tive resections are beyond the scope of this discussion.
Parallel to the development of techniques to identify favo-
rable tumor biology, and having the ability to select
patients who are expected to have a more protracted dis-
ease course (such as in differentiated thyroid cancer and
neuroendocrine tumors) or tumors which are responsive
to systemic therapies (such as colorectal cancer and breast
cancer) more patients will be considered for metastasec-
tomy. PET probe, with further refinements in the design
and technical performance, might prove to be a very use-
ful tool in surgical management of recurrent/metastatic
disease. This study demonstrates the technical ability and
feasibility of FDG-positive lesion detection using a PET
probe.
Currently, with all recognized limitations, FDG imaging
represents a new standard for functional/biologic imaging
in oncology. Many more new PET radiopharmaceuticals
are being developed for distinct tumor types and tumor
phenotypes [18,19]. Peptide-based agents, kinetically and
diagnostically, possess the most favorable radiochemistry.
Cu-64 and Ga-68 labeled octreotide are being increasingly
utilized in detection of occult neuroendocrine tumors
[20]. All PET radiopharmaceuticals have unique biodistri-
bution characteristics defining different in-situ TBR pro-
files, some clearly yielding much better TBR than that of
FDG in a given lesion.
Conclusion
The clinical indications of the PET probe will individually
be determined based on the tumor and patient character-
istics as well as the biodistribution patterns of the selected
PET radiopharmaceuticals. In carefully selected indica-
tions, PET probe can be considered as a useful adjunct in
surgical practice.
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